Please login to the form below

Not currently logged in
Email:
Password:

Hanmi Pharmaceutical

This page shows the latest Hanmi Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

Licensing agreement includes $10m upfront payment. Merck/MSD has reached a licensing agreement with Korea’s Hanmi Pharmaceutical for an investigational GLP-1/glucagon dual receptor agonist for nonalcoholic steatohepatitis (NASH). ... The deal with

Latest news

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    Lilly licensed HM71224 (LY3337641) from South Korean biotech Hanmi Pharmaceutical in 2015 for $50m upfront and milestones of $640m, but after two years of phase II testing has concluded that there ... Hanmi reported the decision to the Korean financial

  • Lilly inks $690m deal with Hanmi for autoimmune drug Lilly inks $690m deal with Hanmi for autoimmune drug

    Hanmi Pharmaceutical. ... HM71224 has shown promising activity in preclinical studies and a phase I study in Europe, according to Gwan Sun Lee, Hanmi's chief executive.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch November 2015 Deal Watch November 2015

    $900m of which two were with the same company, Hanmi Pharmaceutical, a Korean public company. ... Option to co-develop/co-commercialise EU/US. 1, 560. Hanmi Pharmaceutical. Janssen Pharmaceuticals. Licence.

  • Country report: The healthcare market in South Korea Country report: The healthcare market in South Korea

    Dong-A, Yoohan, Hanmi, Green Cross and Choongwhe Pharmaceuticals have led in terms of sales. ... Korea's key players ($m). Ranking. Company. Sales. R&D. 1. Donga Pharmaceutical.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...